ESMO Debate: Should Neoadjuvant Data Be Used To Speed Drug Approval?

Pinterest LinkedIn Tumblr +

VResearchIENNA—Can neoadjuvant breast cancer data be used to accelerate drug development? At the recent annual meeting of the European Society for Medical Oncology, a pro–con argument was conducted in a lively manner meant to incite controversy, convince audience members to change their minds and provide a few laughs in the process. PowerPoint slides even incorporated images of a bullfight with Jose Baselga, MD, PhD, in the arena.

Dr Jose Bacelga

The Pro Argument Dr Jose Baselga

Prof Ian Tannock

The Con Argument
Professor Ian Tannock


Neoadjuvant Data: The Pro Argument

Dr. Baselga, the physician-in-chief at Memorial Sloan-Kettering Cancer Center in New York City, vehemently argued that pathologic complete response (pCR) can be used as a surrogate marker for disease-free survival (DFS) and overall survival (OS). Neoadjuvant trials, he said, provide an efficient trial design for assessing the efficacy of novel therapies. They involve smaller sample sizes, faster trials and less money than large Phase III adjuvant trials…Read more



About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.